KonsultaMD has launched an affordable diabetes screening bundle in the Philippines, priced at P499, to encourage healthier lifestyles. The bundle includes a Fasting Blood Sugar test and a video consultation with a general practitioner. Diabetes is the fourth leading cause of death in the country, affecting 1 in 14 adults. Despite most individuals remaining asymptomatic for 5-7 years before diagnosis, the bundle aims to facilitate early detection and prevention.
The condition primarily impacts individuals who are overweight, those who smoke, drink alcohol regularly, have a family history of diabetes, hypertension, PCOS, or show signs of insulin resistance.
KonsultaMD aims to educate the public about diabetes risk factors and promote timely screening to help prevent related complications.
“Our goal is to empower Filipinos to take charge of their health. By offering an affordable and convenient diabetes screening package, we’re making it easier for individuals to invest in their well-being and potentially detect diabetes in its early stages,” said Beia Latay, KonsultaMD CEO.
KonsultaMD’s bundled plan simplifies the diabetes screening process. Users can easily access the service through the KonsultaMD app, schedule their Fasting Blood Sugar test with a partner diagnostic laboratory, and then consult with a general practitioner available 24/7 to interpret the results.
By promoting early screening, a healthy diet, exercise, and weight management, the company aims to contribute significantly to reducing the impact of diabetes on people’s lives.
This initiative aligns with KonsultaMD’s mission to revolutionize healthcare access in the Philippines. As a portfolio company of 917Ventures, a wholly-owned subsidiary of Globe, KonsultaMD offers comprehensive telehealth services, including 24/7 doctor access, medical certificates, same-day pharmacy delivery, at-home diagnostics, and nursing care for newborns and the elderly.
Filipinos can take advantage of this affordable opportunity by visiting https://konsulta.md or downloading the app on the App Store or Google Play.
